MAY 12, 2016 1:30 PM PDT

The benefits and burdens of assaying matched normal tissue when sequencing cancer genomes

Speaker
  • Lead Bioinformatics Scientist, Personalis, Inc.
    Biography
      Elena Helman joined Personalis, Inc. in January 2014 as a Bioinformatics Scientist, Technical Lead where she has been instrumental in leading the development of the cancer DNA products and pipeline. This includes designing and implementing a somatic analysis pipeline for cancer exome and targeted gene panel sequencing, including small variant and copy-number calling, variant annotation and reporting. Elena received her PhD in Bioinformatics and Integrative Genomics from Harvard-MIT Division of Health Sciences and Technology (HST). For her graduate work in Matthew Meyerson's Lab at the Broad Institute and Dana Farber Cancer Institute, she developed a novel tool to identify somatic retrotransposon insertions using whole-genome and whole-exome next-generation sequencing data from hundreds of tumor samples across The Cancer Genome Atlas (TCGA).

    Abstract

    Targeted sequencing assays are increasingly used to identify tumor mutations that guide therapeutic decisions. Interpretation of a cancer variant’s origin and therapeutic impact poses analytical challenges. Recent studies have indicated that jointly analyzing a tumor with its matched normal can accurately discriminate between somatic and inherited mutations. However, procurement of a matched sample is often logistically impractical. In the absence of a matched normal, large databases and analytical techniques are currently used to identify cancer variants in tumor sequencing data. Whether the benefits outweigh the additional burden of sequencing the matched normal for accurate detection of cancer-relevant mutations remains an open question. For NGS-based cancer interpretation to guide clinical decisions in a practical and cost-effective manner, highly optimized tumor-only and tumor/normal analyses must be available with proper attention to germline consent, classification and education.

    Learning Objectives:

    • Understanding the differences in pipelines, filtering, and use of large population databases necessary depending on the availability of a matched normal
    • Consideration of the burden of secondary findings when sequencing a matched normal 
    • Defining your “actionable” set of variants drastically affects analysis results

    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    FEB 19, 2020 11:00 AM PST
    C.E. CREDITS
    FEB 19, 2020 11:00 AM PST
    DATE: February 19, 2020TIME: 11:00am PST, 2:00pm EST...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    APR 27, 2020 9:00 AM PDT
    C.E. CREDITS
    APR 27, 2020 9:00 AM PDT
    DATE: April 27, 2020 TIME: 9:00am PT, 12:00pm ET Recombinant adeno-associated virus (rAAV) is a small (25-nm) virus that is composed of a protein shell called a capsid and a single-stranded...
    Loading Comments...
    Show Resources